Page 5 - MEMOCiberer014-ENG

The main results aimed at the transfer of technology to the productive sector that we would like to point out, in addition to patents application, include the energy metabolism phenotyping platform, PROTEOmAB, developed in collaboration with the Universidad Autónoma de Madrid-U713-Dr . Cuezva, and the start up from the Rare Diseases Area of the first Spin-Off with participation of the CIBER: Epidisease S .L . Epidisease is an enterprise arising from the activity of Group U733-Dr . Pallardó, of the Universitat de València, specialising in epigenetics applied to the development of new biomarkers with a diagnostic application .
On an international level, it should be pointed out that CIBERER has been nominated in 2014 by the MSSSI to participate in the future Joint Action on Rare Diseases (RD Action), which is the result of the union of the current Ophanet Joint Action and EUCERD Joint Action, which will be active between 2015 and 2017, and funded by the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) of the European Commission . This new participation in a Joint Action is the consequence of the work that has been performed these past few years in the EUCERD Joint Action, leading the studies in quality and improvement of practices in European Centres of Expertise on rare diseases and participation in the future European Reference Networks (ERNs) . The preliminary results of this project were presented in a Workshop held in 2014 in the central office of the Ministry of Health, Social Services and Equality (MSSSI) .
Technical unification of the CIBER in January 2014 will undoubtedly be a step towards the national research collaboration . The primary milestones in this first year include the grant for an integrated CIBER project of excellence entitled “Molecular links between diabetes and neurodegenerative disorders” in collaboration with CIBERDEM, CIBERBBN and CIBERNED, and the grant for a project within the National R&D&I Plan in the MINECO 2014 Networks and Managers call for proposals to develop a CIBER Internationalisation Platform, in which CIBERER, CIBER-BBN and CIBERES collaborate .
CIBERER has continued furthermore to develop and enhance the Transversal Instrument Platforms for RDs (PITER): the CIBERER Biobank, the Animal Phenotyping Platform (SEFALer) and the Bioinformatics Platform for RDs (BIER), thereby maintaining its significant technological support for researchers . As a Spanish Orphanet partner, CIBERER, continues to be part of a transnational project which plays a very relevant role as it unifies specialised knowledge and resources relating to RDs .
All this work conducted within the CIBERER groups naturally yields scientific production (original publications in international journals indexed in ISI-Thompson), which grows year after year in quantity and quality . Furthermore, increasingly more CIBERER work can be found among the most cited Spanish work .
Based on the foregoing, CIBERER has now more than ever the obligation to continue responding to the needs which are involved in being a centre of excellence having these characteristics and the challenges that are coming in the area of RDs on both a social and health level in the next few years .
www .ciberer .es 5